Asepsis Pharmaceuticals Inc. News
July 16th, 2011
Asepsis Pharmaceuticals, Inc. announces the immediate product launch and trademark of; Baclo-IT ™ ( Baclofen Intrathecal Injection ) in 5 ml 2mg/ml Ampoules for México, Guatemala, Costa Rica, Nicaragua, Panamá, Colombia, Ecuador, Peru, Venezuela. Baclofen Intrathecal Injection is indicated for the management of severe spasticity of the spinal cord via a surgically implanted infusion pump system to deliver precise amounts of the baclofen solution. Baclofen is widely prescribed for the treatment of spastic movement disorders, especially in instances of spinal cord injury, spastic cerebral palsy, multiple sclerosis and Lou Gehrig's disease among others. It is estimated that more than 15 million people worldwide are affected with this ailment.
June 14, 2011
Asepsis Pharmaceuticals (India), Inc. announces the product commercialization and trademark of Caspo-Inj. ™ ( Caspofungin Acetate for Injection USP ) in 50 Mg and 70 Mg Vials. Caspofungin is one of the first in the advanced anti-fungal drug class called echinocandis. These antifungals are indicated for the treatment of serious and/or resistant infections. It is often used in patients who cannot use or do not respond to other antifungal medications.
April 7, 2011
Asepsis Pharmaceuticals, Inc. announces the Immediate worldwide product marketing and launch of Amphotericin B Liposome in 10 MG Lyophilized vials for Injection, in a five vial Dial a Dose™ "convenient pack " for pediatric and adult use. Asepsis expects the 50 MG Lyophilized vials due to be released for commercial distribution end of second quarter 2012. Amphotericin B is indicated to be used mainly to treat progressive and potentially life-threatening fungal infections. Amphotericin B Liposome Injection is commonly used to treat cryptococcal meningitis among HIV patients as well as other infections.
July 16, 2011
Asepsis Pharmaceuticals, Inc. announces the immediate product launch and trademark of CMS- Inj.™ (Colistimethate Sodium for Injection USP) in 1 MIU and 2 MIU Vials for India, Sir Lanka, México, Guatemala, Costa Rica, Nicaragua, Panamá, Colombia, Ecuador, Peru, Venezuela. Colistimethate sodium is used to treat Pseudomonas aeruginosa infections in cystic fibrosis patients, however has recently been indicated and received worldwide notice for use in treating multidrug-resistant infection and is one of the last-resort antibiotics for multidrug-resistant Pseudomonas aeruginosa, Acinetobacter and New Delhi metallo-β-lactamase multidrug-resistant Enterobacteriaceae, also known as the New Deli Superbug.
May 12, 2011
Asepsis Pharmaceuticals, Inc. announces the immediate world-wide product marketing and launch of Citicol-Inj.™ ( Citicoline Sodium for injection ) in 250 mg and 1000 mg Single use Vials. Citicoline is widely utilized as a treatment for a disturbance of consciousness due to cerebral trauma and cerebral operation, as well a combination therapy for Parkinson's disease.